It’s not difficult to get Seqster’s CEO Ardy Arianpour fired up, but to get to the details about his business and what he refers to as its “f-ing incredible tech stack,” takes a little doing. Is Seqster a health data analytics company like Clarify Health or Komodo Health, or more of a longitudinal patient health record startup like bWell or Picnic Health?
According to Ardy, these companies would actually make great Seqster clients, and that his tech would serve as the ideal, white-labeled operating system upon which they could engage with patients, collect their data, and examine it alongside EMR data, pharmacy data, social determinants of health data, and even genomic data. While those aforementioned health tech startups might be able to do many of these services themselves, the life sciences companies, health systems, health plans, digital health startups, and non-profit patient registries Seqster does count as clients are using its platform for everything from running decentralized clinical trials to providing patients with a longitudinal single-source medical record.
Ardy breaks down the “operating system” approach Seqster is taking, and how he sees his platform becoming as the “Salesforce of healthcare.” Beyond the specific examples that really bring this concept to life, we talk about what’s ahead for the business, which has raised $23 million in total funding and, interestingly, counts both Takeda Digital Ventures and 23andMe’s CEO and Founder, Anne Wojcicki on its cap table.
Komodo Health has been catching lots of buzz lately thanks to a recently announced partnership with the Chan Zuckerberg Initiative’s Rare as One Network AND some chatter about a possible upcoming IPO that seems to have come from its own CEO Arif Nathoo. To check what’s true and what’s false, we sat down with Komodo’s President, Web Sun.
What did we learn? Well… a lot. The core of both the CZI partnership and the future of Komodo’s business is their Healthcare Map, which Web says draws together the data of more patients (300M+), across a longer period of time (as long as 6-years for some cohorts) than anyone else in the industry. But, this comprehensive, longitudinal view of the patient journey is only part of Komodo’s usefulness – the other part is how they use that dataset to surface insights.
As Web talks about how all this will manifest itself in the context of rare diseases to benefit the patients who belong to the 60 different advocacy organizations that will now have access to Komodo thanks to the CZI partnership, it’s not only easy to understand how comprehensive data can help rare disease patients, but how this is a metaphor for helping all patients across all manner of healthcare. Shortening the diagnostic journey, better understanding symptom patterns and comorbidities, matching patients to specialists highly experienced and adept at managing their conditions, quickly bridging connections to novel therapies and clinical trial opportunities… how beautiful that this will be offered to patients who need it most. The market potential, however, lies in how it will be scaled-up-and-out to the rest of us – which brings us back to those exit rumors! Tune in to hear what Web has to say about his co-founder’s comments, and how he believes Komodo is differentiated from other big data businesses in the analytics space.
You know all that “magic” that machine learning is meant to bring to seemingly lackluster healthcare data and our limited understanding of it? Komodo Health’s co-founder & CEO Arif Nathoo demystifies the wizardry of one of our favorite buzz phrases, “The Algorithm,” and gives us a colorful overview of how his startup is making data useful to the way payers, health systems, and pharma co’s study populations at-scale. Komodo’s raised $314M to-date, closing a MASSIVE $220M Series E backed by Tiger Global Management, Casdin Capital, ICONIQ Growth, Andreessen Horowitz, and SVB Capital in April, and after hearing this enthusiastic explanation of what they’re working on – and the market potential for it – we understand why.
At its most simplistic, Komodo is using de-identified healthcare claims data as a base from which to learn how patients flow through the healthcare system. Other data sets are brought in and layered onto that “patient-flow, dollar-flow” claims trail in effort create a new vantage point for seeing what’s happening within the system, at a population level. That insight can then be used to predict patient behavior and provide evidenced analysis for how the system can be improved. Don’t worry: Arif provides lots of detailed examples and talks through exactly what kind of data can (and currently can’t) be pulled into the mix. If you want to get smart on the “Big Data” opportunity in healthcare and how it’s going to be impacting the future of care delivery and virtual care delivery, this is one chat you won’t want to miss!
On Episode 193 of Health in 2 Point 00, we have another huge day! We catch up on Amazon’s telehealth news before covering more massive deals. Evidation gets $153 million, bringing their total to a whopping $259 million and Komodo Health gets $220 million, bringing their total to $319 million. Bigfoot Biomedical raises $53 million for Type 1 diabetes care, and Glooko raises $30 million for their management system primarily working with diabetes clinics. —Matthew Holt
Today on Health in 2 Point 00, Jess admires my new COVID-safe ski gear, designed to provide the right amount of coverage to the right part of your face at the right time. On Episode 178, Jess asks me about Talkspace finally getting its SPAC IPO together with a $1.4 billion valuation – this was a long time coming. Accolade acquires 2nd.MD for $460 million, Dina Health raises $7 million in a Series A, and Komodo Health raises $44 million and acquires the consulting business from Mavens. —Matthew Holt
On today’s Health in 2 Point 00, Jessica is distracted playing video games, and rants about the unbearable maleness of wearables. Meanwhile Komodo Health raises $50m for more analytics (presumably of patients playing Pong), Picnic Health gets $25m as PHRs will not go away, Hazel Health gets $33 million to take telehealth back to school, and then there’s Amazon Halo — and our stars’ alter egos make an appearance — Matthew Holt
Today on Health in 2 Point 00, Jess and I have a million deals to talk through. My Softbank rumor from last week hasn’t been announced yet, but there’s still plenty to discuss before JP Morgan. In this episode, get key takeaways from OneMedical’s S1, Swedish company KRY raising $155 million, ClassPass reaching unicorn status with a $285 million round, Komodo Health raising $50 million, and LeanTaaS raising $40 million. Be sure to follow along with all the JPMadness next week. —Matthew Holt
Listen to them on Itunes or Spotify
Subscribe to our mailing list
Want to Partner with THCB?
View our Advertisement & Sponsorship Prospectus here